Strategic Distribution Growth Recent exclusive private label distribution with Smith & Nephew demonstrates strong OEM-ready demand for biodynamic PRP wound care. Use this precedent to approach large wound-care distributors and hospital networks with private-label or co-branded Aurix-based solutions to rapidly expand US market access and credibility.

Channel Expansion Opportunities Past distributor collaborations (Pacific Medical) show willingness to partner. Map out additional channel partners with national footprints in wounds, orthopedics, and diabetes care; propose joint marketing funds, clinician training, and stock-keeping arrangements to accelerate adoption of Aurix at point-of-care.

Autologous Advantage Aurix uses the patient’s own platelets and plasma, offering autologous therapy with potentially lower immunogenic risk and streamlined regulatory considerations. Position to wound-care centers treating chronic ulcers and diabetic populations, highlighting faster healing and reduced supply-chain complexity; develop clinician-facing case studies to support adoption.

Strategic Financing Signals With mid-market revenue and a focused team, there is room to scale through partnerships rather than a large internal sales expansion. Explore strategic investments or joint ventures to fund manufacturing, logistics, and expanded sales efforts, leveraging investor-backed growth trends in regenerative wound care.

Competitive Differentiation Differentiation centers on autologous biodynamics, point-of-care delivery, and partnerships with established brands. Craft messaging that contrasts Aurix with allogeneic products and highlight workflow fit in clinics; target procurement and clinical leads at hospital systems and wound-care networks for faster procurement cycles.